drugset
drugset / Trial / NCT03207256

Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials

NCT03207256 ↗

Phase 2 Terminated 51 enrolled TG Therapeutics, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open label compassionate use trial of Ublituximab and TGR-1202 in combination or as single agents in patients currently receiving treatment on Ublituximab and/or TGR-1202 trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.

Timeline

Start
2017-08-09
Primary completion
2022-05-25
Completion
2022-06-24

Outcome

Outcome not reported

Stopped (Business): “Strategic/Business Decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject Ublituximab Monoclonal antibody — Intravenous
Subject Umbralisib Small molecule — Oral

Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma